Fibrogen announces completion of the pamrevlumab arm in precision promise, pancreatic cancer action network's phase 2/3 adaptive platform trial for metastatic pancreatic cancer

San francisco, jan. 25, 2024 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) announced graduation and completion of the pamrevlumab experimental arm in the pancreatic cancer action network's (pancan) precision promisesm phase 2/3 adaptive platform trial, which evaluates pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma (mpdac). topline data from this registration study is anticipated in the second quarter of 2024.
FGEN Ratings Summary
FGEN Quant Ranking